Drug intelligence / Profile preview

murine Interleukin-12 mRNA (mIL12 mRNA)

Development stage: Preclinical
Lead developer: Moderna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intratumoral Injection

Overview

mIL12 mRNA is an mRNA-based drug that encodes for murine Interleukin-12 (IL-12), a cytokine involved in the immune response. It is used intratumorally to induce anti-tumor immune responses by activating cytotoxic T cells and modulating the tumor microenvironment. The administration of mIL12 mRNA has shown effectiveness in murine tumor models by enhancing PD-L1 efficacy and promoting durable complete responses in checkpoint inhibitor-resistant tumors[1][2].

Targets

IL-12R (Interleukin-12 receptor)

Beyond the preview

Go deeper on murine Interleukin-12 mRNA (mIL12 mRNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on murine Interleukin-12 mRNA (mIL12 mRNA).

Explore the full profile